The patent covers compounds including Triolex and formulations that contain the drug or the other claimed compounds.
Harbor BioSciences said that Triolex is a compound for the treatment of responsive insulin resistant pre-diabetes and type 2 diabetes patients, operating by limiting inflammation in responsive patient populations.